News Releases

Date	Title	View
December 19, 2024	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005	PDF Version
November 14, 2024	Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024	PDF Version
November 13, 2024	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements	PDF Version
November 4, 2024	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference	PDF Version
September 27, 2024	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study	PDF Version
September 3, 2024	Alumis to Participate in Upcoming September Investor Conferences	PDF Version
August 13, 2024	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements	PDF Version
July 29, 2024	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis	PDF Version
June 27, 2024	Alumis Announces Pricing of Initial Public Offering	PDF Version
April 30, 2024	Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005	PDF Version